AXIM Axim Biotechnologies Inc (QB)

CUSIP No. 05463J 107

2

Item 1.

  Security and Issuer

This Schedule 13D relates to the common stock, par value $.0001 per share, (the “Shares”) of AXIM International, Inc., a Nevada corporation (the “Company” or the “Issuer”).  The principal executive offices of the Company are 18 East 50 ^th Street, 5th Floor, New York, NY 10022.

Item 2.

  Identity and Background

(a)

This statement is filed by Sanammad Foundation (the “Reporting Person”) a Netherlands Foundation.

(b)

The Reporting Person’s address is 18 East 50 ^th Street, 5 ^th Floor, New York, NY 10022.

(c)

The Reporting Person is not an officer and director of Issuer.

(d)

The Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.

(e)

The Reporting Person has not been a party to a civil proceeding of a judicial or administrative body resulting in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws.

Item 3.

  Source and Amount of Funds or Other Consideration

Personal funds, $34,800.

Item 4.

  Purpose of Transaction

The purpose of this Schedule 13D is to report the acquisition of 14,943,650 shares by the Reporting Person.

The Shares held by the Reporting Person were acquired for investment purposes in the ordinary course of Reporting Person’s business or investment activities, as the case may be.

The Reporting Person may acquire additional Shares, dispose of all or some of these Shares from time to time, in each case in open market or private transactions, block sales or purchases or otherwise, or may continue to hold the Shares, depending on business and market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors.

The Reporting Person may engage in communications with management, one or more shareholders, officers or directors of the Issuer, including discussions regarding the Issuer's operations and strategic direction that, if effected, could result in, among other things:

(1)

the acquisition of additional shares of the Issuer, or the disposition of shares of the Issuer;

(2)

an extraordinary corporate transactions, such as a merger, reorganization or liquidation, involving the Issuer;

(3)

a sale or transfer of a material amount of assets of the Issuer;

(4)

any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

(5)

any material change in the present capitalization or dividend policy of the Issuer;

(6)

any other material change in the Issuer's business or corporate structure;

(7)

changes in the Issuer's charter, by-laws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;

(8)

causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted on an inter-dealer quotation system of a registered national securities

(9)

association;

(10)

a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; and/or

(11)

any action similar to those enumerated above.

3

The Reporting Person reserves the right, based on all relevant factors and subject to applicable law, at any time and from time to time, to review or reconsider Reporting Person’s position, change Reporting Person’s purpose, take other actions (including actions that could involve one or more of the types of transactions or have one or more of the results described in paragraphs (a) through (j) of Item 4 of  Schedule 13D) or formulate and implement plans or proposal with respect to any of the foregoing.

Any future decision of the Reporting Person to take any such actions with respect to the Issuer or its securities will take into account various factors, including the prospects of the Issuer, general market and economic conditions and other factors deemed relevant.

Item 5.  Interest in Securities of the Issuer

(a)

The aggregate number of shares of common stock to which this Schedule 13D relates is 14,943,650 shares.  The shares represent approximately 45% of the common stock outstanding as of March 21, 2014.  In addition, the Reporting Person holds 500,000 shares of company Preferred stock. Each share of preferred stock is entitled to 100 votes on all matters submitted to the shareholders of the Company.  The preferred stock does not have any conversion rights.

(b)

Reporting Person has sole voting and dispositive power over the shares of common stock and preferred stock in which Reporting Person owns.  

(c)

See Item 3, above.

(d)

Not Applicable.

(e)

Not Applicable.

Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

None.

Item 7.

  Material to Be Filed as Exhibits

Exhibit 1.   Securities Purchase Agreement dated March 17, 2014.

Exhibit 2.  Agreement for Purchase of Common Stock dated March 17, 2014.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

4

Exhibit 1

Exhibit 2